You are here: Industry Insights > CMAB

News List

WuXi Biologics to acquire CMAB Biopharma Group expresspharma
March 19, 2021
WuXi Biologics announced it has entered into a purchase agreement with CBC Group (CBC), a healthcare-dedicated investment firm, and other companies including Ming Bioventures under which WuXi Bio will acquire over 90 per cent interest of CMAB ...
CMAB Biopharma Congratulates Partner Junshi Biosciences on NMPA Acceptance of Application for a Clinical Trial of its PD-1/TGF-β Bifunctional Fusion Protein prnasia
March 08, 2021
Recently, CMAB Biopharma (Suzhou) Inc's partner Shanghai Junshi Biosciences Co., Ltd., announced that a clinical trial application for its PD-1/TGF-β bifunctional fusion protein JS201 injection (JS201) has been accepted by National Medical Products ...
CMAB Biopharma Congratulates Partner Innovent Biologics on FDA Clearance of IND Application of its COVID-19 Antibody Project prnasia
March 04, 2021
CMAB Biopharma (Suzhou) Inc. congratulates its partner Innovent Biologics, Inc. on the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for its antibody candidate which targets the COVID-19 virus ...
CMAB Completes Devt. and Mfg. Project for QureBio contractpharma
May 15, 2020
Bispecific antibody Q-1802 will enter clinical trials to assess treatment of solid tumors such as gastric cancer.
CMAB Bolsters Executive Team contractpharma
April 06, 2020
CMAB Biopharma (Suzhou) Inc., a biologics contract manufacturing and development organization (CDMO), has appointed Ye Shi as the head of quality.
CMAB Biopharma and Fapon Biopharma Sign Agreement to Develop and Manufacture a Biologic Oncology Asset En-CPhI.CN
December 03, 2019
CMAB Biopharma (Suzhou) Inc., a pure-play, biologics contract manufacturing and development organization (CDMO) and Shenzhen Fapon Biopharma Inc. ...
CMAB Biopharma and BJ Bioscience Establish an Exclusive Strategic Partnership En-CPhI.CN
October 12, 2019
CMAB Biopharma (Suzhou) Inc. ("CMAB"), a pure-play biologics CDMO and BJ Bioscience Inc. ("BJ Bioscience"), an innovative biopharmaceutical enterprise ...
CMAB Receives Positive Opinion Following External Quality Audit contractpharma
September 12, 2019
CDMO’s fully integrated facility in Suzhou, China was found to conform to EU Eudralex Vol. 4 GMP guidelines.
CMAB and Kintor Enter Mfg. Tie-up contractpharma
August 26, 2019
Collaboration aims to develop and manufacture the ALK-1 monoclonal antibody.
CMAB, Kintor announce comprehensive collaboration biospectrumasia
August 22, 2019
China based CMAB Biopharma Inc. (CMAB), a pure-play CDMO business in biologics and Suzhou Kintor Pharmaceuticals, Inc. (Kintor), an innovative biopharmaceutical enterprise, have announced a comprehensive strategic cooperation agreement for the development